En vurdering af LeukoScans potentielle kliniske betydning viste, at LeukoScan kunne ændre den kliniske behandling i 50, 2% eller forbedre det kliniske resultat i 43, 4% af de 175 evaluerbare patienter med mulig osteomyelitis.
An evaluation of potential clinical impact of LeukoScan demonstrated that LeukoScan could change clinical management in 50.2% or improve clinical outcome in 43.4% of the 175 evaluable patients with suspected osteomyelitis.